Podcast

Speaking of Urology: What patients undergoing HIFU should expect postoperatively

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

Catch up on "Speaking of Urology":

A HIFU expert discusses his treatment criteria

Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Related Videos
Jaspreet S. Sandhu, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Standard pathology reports may be difficult to understand for patients with prostate cancer
January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC
January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke
Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.
Expanded indication sought for darolutamide in mHSPC in China
January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke
The application is supported by data from the pivotal phase 3 ARANOTE trial.
© 2025 MJH Life Sciences

All rights reserved.